The Middle East and Africa (MEA) antirheumatic drugs market was valued at US$10,727.154 million in 2019. The market in the Middle East and Africa region is poised to show healthy growth throughout the forecast period primarily on account of the presence of a well-established and state-of-art pharmaceutical industry in the region. The presence of a vast number of domestic pharmaceutical manufacturing companies is also considered to be a major factor driving the antirheumatic drugs market growth in the Middle East and Africa region during the next five years. Furthermore, the growing focus of the governments of various gulf countries towards the development of a non-oil economy and boost the investments in other key areas. This, in turn, is projected to propel the opportunities for the market to grow in the near future as an increase in the investments in the R&D across the pharmaceutical sector of the region is anticipated in the coming years. Furthermore, the inclining focus of the government enhancement of the healthcare services for the well-being of the growing population is further leading to the timely delivery of medical equipment and a constant supply of medicines is anticipated to be a major factor for the promising growth of the pharmaceutical sector of this region.
Moreover, the presence of well-established healthcare facilities in many developed countries of the region coupled with the higher purchasing power of the people further increases the demand for costly medical treatments and services, thereby expected to positively drive the market growth in the region during the next five years. Additionally, a promising demographic shift and an increase in the life expectancy rate has significantly increased the geriatric population of the Middle East and Africa region. This, in turn is expected to significantly drive the demand for various drugs for the treatment of various age-associated diseases that includes inflammatory disorders, chronic backache, and joint pains among others, and further positively impact the market growth.
The Middle East and Africa (MEA) antirheumatic drugs market has been segmented on the basis of the type of disease, type of molecule, and sales channel. On the basis of the type of disease, the market has been classified on the basis of osteoarthritis, rheumatoid arthritis, gout, lupus, and others.By the type of molecule, the market has been segmented on the basis of pharmaceuticals and biopharmaceuticals. By the sales channel, the segmentation has been done on the basis of prescription and over-the-counter (OTC). On the basis of the country, the segmentation has been done on the basis of Saudi Arabia, Israel, Nigeria, Ethiopia, Egypt, Iran, Turkey, and South Africa.